Actinium Pharmaceuticals Inc (ATNM) Stock up 15% After Rating Increased to ‘Buy’

Share

Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) shares are trading up big in mid afternoon trading today after Zack’s Investment Research upgraded the stock from a “hold” to a “buy” rating. While this seems to be one of the main reasons for today’s jump in price, we also must keep in mind that FBR & Company also put a “buy” rating on this stock back in late November – with a price target of $12.00.

These new ratings have investors hoping for institutional investments, as well as perhaps a buyout in the future. It should be interesting to follow this stock in trading later this week to see if the price retreats back down or continues to increase.

The stock is up 14.98% or $0.34 following the news, hitting $2.61 per share. About 2.17M shares traded hands or up 314.12% from the average. ATNM has declined 6.20% since May 18, 2015 and is currently downtrending. It has underperformed the S&P500 by 3.93%.

The institutional sentiment decreased to 0.65 in Q2 2015. It’s down 0.23, from 0.88 in 2015Q2. The ratio turned negative, as 13 funds sold all their Actinium Pharmaceuticals Inc shares they owned while 7 reduced their positions. 3 funds bought stakes while 10 increased their total positions. Institutions now own 7.12 million shares which is 192.34% more than the previous share count of 2.44 million in 2015Q2.

Dafna Capital Management Llc holds 0.16% of its total portfolio in Actinium Pharmaceuticals Inc, equating to 90,000 shares. Bridgeway Capital Management Inc owns 160,200 shares representing 0.01% of their total US portfolio. Moreover, Vanguard Group Inc has 0.01% of their total portfolio invested in the company, equating to 5.63 million shares. The New York-based American International Group Inc has a total of 0% of their portfolio invested in the stock. Balyasny Asset Management Llc, a Illinois-based fund reported 11,100 shares owned.

Actinium Pharmaceuticals, Inc. is a biopharmaceutical firm engaged in developing therapies for diseases using its alpha particle immunotherapy (APIT) platform and other related technologies. The company has a market cap of $95.02 million. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131). It currently has negative earnings. As of December 31, 2014, Actinium’s Actimab-A was in human clinical trials stage for acute myeloid leukemia (AML) and Iomab-B in clinical trial stage for use in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications.

COMMENTS: